000136038 001__ 136038
000136038 005__ 20240229105051.0
000136038 0247_ $$2doi$$a10.1007/s00259-018-3972-9
000136038 0247_ $$2pmid$$apmid:29478079
000136038 0247_ $$2ISSN$$a0340-6997
000136038 0247_ $$2ISSN$$a1432-105X
000136038 0247_ $$2ISSN$$a1619-7070
000136038 0247_ $$2ISSN$$a1619-7089
000136038 0247_ $$2altmetric$$aaltmetric:34729649
000136038 037__ $$aDKFZ-2018-00737
000136038 041__ $$aeng
000136038 082__ $$a610
000136038 1001_ $$00000-0001-8739-8741$$aSachpekidis, Christos$$b0$$eFirst author
000136038 245__ $$aThe role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma.
000136038 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2018
000136038 3367_ $$2DRIVER$$aarticle
000136038 3367_ $$2DataCite$$aOutput Types/Journal article
000136038 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1531126435_16865
000136038 3367_ $$2BibTeX$$aARTICLE
000136038 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136038 3367_ $$00$$2EndNote$$aJournal Article
000136038 520__ $$aThe aim of the present study was to assess the value of interim 18F-FDG PET/CT performed after the first two cycles of ipilimumab treatment in the prediction of the final clinical response to this type of immunotherapy.The study group comprised 41 patients with unresectable metastatic melanoma scheduled for ipilimumab therapy. Whole-body 18F-FDG PET/CT was performed before the start of ipilimumab treatment (baseline PET/CT) and after the initial two cycles of ipilimumab treatment (interim PET/CT). Evaluation of patient response to treatment was based on the European Organization for Research and Treatment of Cancer (EORTC) 1999 criteria for PET as well as the recently proposed PET Response Evaluation Criteria for Immunotherapy (PERCIMT). The patients' best clinical response, assessed at a median of 21.4 months (range 6.3-41.9 months) was used as reference.According to their best clinical response, the patients were divided into two groups: those showing clinical benefit (CB) including stable disease, partial response and complete response (31 patients), and those showing no clinical benefit (no-CB including progressive disease (10 patients). According to the EORTC criteria, interim PET/CT demonstrated progressive metabolic disease (PMD) in 20 patients, stable metabolic disease (SMD) in 11 patients, partial metabolic response (PMR) in 8 patients, and complete metabolic response (CMR) in 2 patients. According to the PERCIMT, interim PET/CT demonstrated PMD in 9 patients, SMD in 24 patients, PMR in 6 patients and CMR in 2 patients. On the basis of the interim PET, the patients were divided in a similar manner to the division according to clinical response into those showing metabolic benefit (MB) including SMD, PMR and CMR, and those showing no metabolic benefit (no-MB) including PMD. According to this dichotomization, the EORTC criteria showed a sensitivity (correctly predicting CB) of 64.5%, a specificity (correctly predicting no-CB) of 90.0%, a positive predictive value (PPV) of 95.2%, a negative predictive value (NPV) of 45.0% and an accuracy of 70.7% in predicting best clinical response. The PERCIMT showed a sensitivity of 93.6%, a specificity of 70.0%, a PPV of 90.6%, a NPV of 77.8% and an accuracy of 87.8%. The McNemar test showed that the PERCIMT had a significantly higher sensitivity than EORTC criteria (p = 0.004), while there was no significant difference in specificity (p = 0.5). The agreement between the two sets of criteria was poor (McNemar test p = 0.001, and accordingly kappa = 0.46).The application of the recently proposed PERCIMT to interim 18F-FDG PET/CT provides a more sensitive predictor of final clinical response to immunotherapy than the application of the EORTC criteria in patients with metastatic melanoma.
000136038 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000136038 588__ $$aDataset connected to CrossRef, PubMed,
000136038 7001_ $$0P:(DE-He78)46d923d9b44b8aaaf3179c5f6f7adf81$$aAnwar, Hoda Nagui Mohamed Abdelwahab$$b1$$udkfz
000136038 7001_ $$aWinkler, Julia$$b2
000136038 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b3$$udkfz
000136038 7001_ $$0P:(DE-He78)f89c856740c99008f4fbc1efa501d4f9$$aLarribere, Lionel$$b4$$udkfz
000136038 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b5$$udkfz
000136038 7001_ $$aHassel, Jessica C$$b6
000136038 7001_ $$0P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDimitrakopoulou-Strauss, Antonia$$b7$$eLast author$$udkfz
000136038 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-018-3972-9$$gVol. 45, no. 8, p. 1289 - 1296$$n8$$p1289 - 1296$$tEuropean journal of nuclear medicine and molecular imaging$$v45$$x1619-7089$$y2018
000136038 909CO $$ooai:inrepo02.dkfz.de:136038$$pVDB
000136038 9101_ $$0I:(DE-588b)2036810-0$$60000-0001-8739-8741$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000136038 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)46d923d9b44b8aaaf3179c5f6f7adf81$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000136038 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000136038 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f89c856740c99008f4fbc1efa501d4f9$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000136038 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000136038 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000136038 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000136038 9141_ $$y2018
000136038 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136038 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136038 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136038 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136038 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136038 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2015
000136038 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136038 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136038 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136038 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136038 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000136038 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136038 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2015
000136038 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lKKE Nuklearmedizin$$x0
000136038 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000136038 9201_ $$0I:(DE-He78)G300-20160331$$kG300$$lKKE Dermatoonkologie$$x2
000136038 980__ $$ajournal
000136038 980__ $$aVDB
000136038 980__ $$aI:(DE-He78)E060-20160331
000136038 980__ $$aI:(DE-He78)C060-20160331
000136038 980__ $$aI:(DE-He78)G300-20160331
000136038 980__ $$aUNRESTRICTED